Financial Performance - For the fiscal year ending March 31, 2023, the company's revenue increased by approximately 6.6% to about HKD 76.7 million from approximately HKD 72 million for the previous year[10]. - Gross profit rose by approximately HKD 3.2 million or 8.7% to about HKD 39.5 million, with the gross profit margin increasing from approximately 50.5% to 51.5%[11]. - The company's net profit increased from approximately HKD 4 million to about HKD 7.6 million, primarily due to increased revenue and a one-time government subsidy for employment retention[15]. - Administrative and other operating expenses rose by approximately HKD 1.3 million or 4.2% to about HKD 30.5 million, mainly due to increased rent and management fees[12]. - The tax expense for the fiscal year was approximately HKD 1.8 million, up from HKD 1.4 million in the previous year[13]. - The interim dividend declared for the year ending March 31, 2023, is HKD 0.4 per share, an increase from HKD 0.3 per share in 2022[16]. - The company reported a strong performance for the fiscal year ending March 31, 2023, with a total revenue increase of 15% compared to the previous year[56]. - Total revenue for the reporting period was approximately HKD 76.7 million, an increase from HKD 72 million in the previous fiscal year, representing a growth of about 9.72%[159]. Market Outlook and Strategy - The company is optimistic about the healthcare sector's future, driven by an aging population and increased health awareness in Hong Kong[6]. - A joint venture has been established to promote the development of autonomous mobile robotic solutions in the healthcare industry[9]. - The company plans to further diversify its product offerings and enhance customer service to improve its one-stop medical equipment solution[9]. - The economic recovery following the lifting of COVID-19 restrictions has positively impacted revenue from medical equipment and supplies[10]. - The company is actively seeking suitable investment opportunities to achieve business diversification and enhance shareholder returns[6]. - New product launches are anticipated to contribute significantly to revenue, with an estimated impact of DD million in the upcoming quarter[45]. - Market expansion efforts are underway, targeting new regions with a projected market size of $FF billion[45]. - The company is exploring potential acquisitions to enhance its market position, with a focus on companies valued at GG million[45]. - Strategic partnerships are being formed to leverage synergies, aiming for a combined revenue increase of HH%[45]. Corporate Governance - The board of directors has maintained a high level of corporate governance, adhering to all relevant guidelines and principles[57]. - The company has complied with GEM listing rules by appointing at least 3 independent non-executive directors, with one possessing relevant financial expertise[69]. - The chairman and CEO roles are held by the same individual, Ms. Huang, who is responsible for overall strategy and major decisions[71]. - The audit committee held 5 meetings during the fiscal year ending March 31, 2023, reviewing financial reports and risk management procedures[78]. - The audit committee is composed of 2 independent non-executive directors and 1 non-executive director[75]. - The company has established a remuneration committee in compliance with GEM listing rules since March 1, 2018[80]. - The board regularly reviews the performance of management and requires board approval for significant transactions[68]. - The company ensures that all directors can seek independent professional advice at the company's expense[73]. - The board is committed to maintaining high standards of corporate governance and compliance with relevant regulations[77]. Environmental, Social, and Governance (ESG) Initiatives - The company emphasizes sustainable development as key to long-term success and has integrated environmental, social, and governance (ESG) principles into its business strategy[134]. - A working group has been established to enhance employee awareness of ESG issues and to collect and analyze relevant data[139]. - The company aims to create sustainable value for shareholders while pursuing a responsible and sustainable business model[138]. - The environmental, social, and governance (ESG) report focuses on the group's operations as a medical device distributor in Hong Kong, which is the main source of revenue[145]. - Key ESG issues identified include greenhouse gas emissions, waste management, resource usage, and climate change, among others[151]. - The group is committed to continuous evaluation of its ESG risk management and internal control systems to improve performance and data collection[151]. - The company has adopted a corporate social responsibility policy focused on waste management principles, including reduction, reuse, recycling, and alternative use[156]. - The company aims to reduce greenhouse gas emissions and has set a target to maintain or lower emissions density by the fiscal year ending March 31, 2030[157]. Employee Development and Training - The company has hired additional personnel, including seven product representatives and two engineers, to expand its workforce[34]. - Employee development programs have been enhanced, with a focus on training that has improved staff retention rates by 15%[56]. - Approximately 39% of employees received training during the reporting period, down from 100% in FY2022[195]. - Average training hours per employee decreased to 9.0 hours in FY2023 from 9.9 hours in FY2022[195]. - Senior management training hours increased significantly from 2.0 hours in FY2022 to 3.4 hours in FY2023, an increase of 70%[199]. - The company maintained a zero-tolerance policy towards any form of workplace harassment or abuse[189]. Risk Management - The company has established a risk management policy to identify, assess, and manage key risks affecting the business, with regular quarterly reviews[109]. - The board confirmed that there are no significant deficiencies in the company's risk management and internal control systems[110]. - The company has adopted a whistleblowing policy to promote a culture of compliance and ethical behavior, with no significant fraud or misconduct reported for the fiscal year ending March 31, 2023[111]. - The company has implemented an anti-corruption policy as part of its corporate governance framework, ensuring adherence to applicable anti-corruption laws and regulations[113].
君百延集团(08372) - 2023 - 年度财报